scholarly journals GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome

Cell Genomics ◽  
2021 ◽  
Vol 1 (3) ◽  
pp. 100069
Author(s):  
Ferdinando Bonfiglio ◽  
Xingrong Liu ◽  
Christopher Smillie ◽  
Anita Pandit ◽  
Alexander Kurilshikov ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Motility ◽  
Stool Frequency ◽  
Irritable Bowel

scholarly journals Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine

2011 ◽  
Vol 48 (1) ◽  
pp. 36-40 ◽  
Author(s):  
Mauro Bafutto ◽  
José Roberto de Almeida ◽  
Nayle Vilela Leite ◽  
Enio Chaves Oliveira ◽  
Salustiano Gabriel-Neto ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Symptom Score ◽  
Stool Frequency ◽  
Total Symptom Score ◽  
Stool Consistency ◽  
Mucosal Inflammation ◽  
Irritable Bowel Syndrome Group ◽  
Irritable Bowel ◽  
Postinfectious Irritable Bowel Syndrome

CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown. OBJECTIVE: To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. METHODS: Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4). RESULTS: Postinfectious irritable bowel syndrome group presented a statistically significant reduction of the total symptom score (P<0.0001). The stool frequency was significantly reduced (P<0.0001), and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distension were significantly reduced (P<0.0001). Noninfective irritable bowel syndrome group presented a statistically significant reduction of total symptom score (P<0.0001). Also, the stool frequency was significantly reduced (P<0.0001) and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distention were significantly reduced (P<0.0001). There was no statistical difference between postinfectious irritable bowel syndrome group and noninfective irritable bowel syndrome group on total symptom score results at 30th day of therapy with mesalazine 800 mg 3 times a day. (P = 0.13). CONCLUSION: Mesalazine reduced key symptoms of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients.

scholarly journals Interstitial Cells of Cajal: A Novel Hypothesis for the Pathophysiology of Irritable Bowel Syndrome

2011 ◽  
Vol 25 (5) ◽  
pp. 277-279 ◽  
Author(s):  
Ahad Eshraghian ◽  
Hamed Eshraghian
Keyword(s):  
Irritable Bowel Syndrome ◽  
General Practitioners ◽  
Gastrointestinal Motility ◽  
Interstitial Cells Of Cajal ◽  
Interstitial Cells ◽  
High Prevalence ◽  
Number Of Visits ◽  
Irritable Bowel ◽  
Almost All ◽  
Cells Of Cajal

Irritable bowl syndrome (IBS) affects a large proportion of the world’s population, and accounts for a considerable number of visits to gastroenterologists and general practitioners. Despite its high prevalence, the precise mechanism of IBS has not been identified to date. The interstitial cells of Cajal (ICC) participate in the production of slow waves and the regulation of their propagation through the gastrointestinal system; thus, they are important components of gastrointestinal motility. The present review proposes that ICC play a central role in the pathophysiology of IBS. This hypothesis is based on many links between ICC and currently proposed mechanisms of IBS pathophysiology. It appears that ICC may be involved in almost all of the previously explained pathogenic mechanisms of IBS. If proven, this hypothesis may provide a key to solving the IBS mystery.

scholarly journals Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis

2017 ◽  
Vol 10 (3) ◽  
pp. 311-322 ◽  
Author(s):  
Pere Clavé ◽  
Jan Tack
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Pooled Analysis ◽  
Stool Frequency ◽  
Global Response ◽  
Intention To Treat ◽  
Therapeutic Benefits ◽  
Irritable Bowel ◽  
To Receive ◽  
Significant Therapeutic Effect

Background: Otilonium bromide (OB) is a spasmolytic agent acting as an L-type calcium channel antagonist in intestinal and colonic smooth muscle cells (SMCs). We analyzed three independent clinical trials with homogeneous design on patients with irritable bowel syndrome (IBS). After 2 weeks receiving placebo, patients were randomized to receive OB (3 × 40 mg daily) or placebo for 15 weeks. We aimed to perform a pooled analysis of the data from these homogeneous clinical trials to evaluate the efficacy of OB treatment on symptoms and global response of patients. Methods: A total of 883 patients with IBS (69.8% women, mean age 46.2 years, 43.8% mixed type) were included, 442 treated with OB and 441 with placebo. The efficacy results from the three studies at weeks 5, 10 and 15 were pooled in an intention-to-treat (ITT) strategy, analyzed with a logistic regression model and described by forest plots. Results: Despite a placebo effect in all efficacy variables, a significant therapeutic effect of OB was observed at weeks 10 and 15 with reference to: (a) intensity and frequency of abdominal pain; (b) rate of responders as evaluated by patients (71.8% at week 10 and 77.2% at week 15); (c) severity of bloating; (d) rate of responders as evaluated by physicians (55% at week 10 and 63.9% at week 15). No significant OB effect was observed in stool frequency and consistency. Conclusions: OB is more effective than placebo in IBS treatment. Therapeutic benefits are significant after 10 weeks and are maximal after 15 weeks of treatment.

S1256 Gut Permeability and Stool Frequency Are Correlating in Diarrhea-Predominant Irritable Bowel Syndrome

2009 ◽  
Vol 136 (5) ◽  
pp. A-223
Author(s):  
Krisztina Gecse ◽  
Richárd Róka ◽  
Emese Séra ◽  
András Rosztóczy ◽  
Ferenc Izbeki ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Stool Frequency ◽  
Gut Permeability ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document